Muscle Wasting -SARCOPENIA

---

SNP Therapeutics has developed an algorithm that can identify individuals who have difficulty converting protein into muscle mass. Up to 10% of the population has difficulty creating muscle mass due to (variant genes) or SNPs preventing the proper metabolism of one carbon nutrients.  Thirty Two Million Americans suffer with Muscle wasting. The market is forecast to grow to nearly $4Bn by 2024. 

SNP Therapeutics is well positioned to participate in this growing market with potential products focusing in the Sports Nutrition and Aging Consumer Health segments. Additionally, the company is interested in pursuing prescription markets and is open to partnerships with ethical companies to develop clinical studies focused on these populations.